Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,012.51 -59.12 (-1.17%) Dow
37,840.62 -620.30 (-1.61%) Nasdaq
15,498.08 -214.67 (-1.37%) Bitcoin USD
63,641.85 -1,801.89 (-2.75%) CMC Crypto 200
1,378.46 -4.11 (-0.30%)
FibroGen, Inc. (FGEN)
| Previous close | 0.9843 |
| Open | 0.9500 |
| Bid | 0.9320 x 100 |
| Ask | 0.9635 x 100 |
| Day's range | 0.9011 - 0.9892 |
| 52-week range | 0.3330 - 19.4700 |
| Volume | |
| Avg. volume | 2,814,580 |
| Market cap | 93.793M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois. Details for the poster presentation are as foll
- GlobeNewswire
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% of patients Confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug
- GlobeNewswire
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference. The live audio webcast of the event will be available to investors and other interested p
